|
UBE2O expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.44079986724921E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.19749998595387E-09 |
| Normal-vs-Stage2 |
5.691200E-01 |
| Normal-vs-Stage3 |
6.21092066666051E-12 |
| Normal-vs-Stage4 |
2.55040000229911E-09 |
| Stage1-vs-Stage2 |
5.963700E-03 |
| Stage1-vs-Stage3 |
2.257700E-02 |
| Stage1-vs-Stage4 |
7.505700E-02 |
| Stage2-vs-Stage3 |
1.627800E-04 |
| Stage2-vs-Stage4 |
3.236700E-04 |
| Stage3-vs-Stage4 |
9.571000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.50579573652021E-11 |
| Normal-vs-AfricanAmerican |
1.778800E-01 |
| Normal-vs-Asian |
5.27279997442065E-10 |
| Caucasian-vs-AfricanAmerican |
2.306800E-01 |
| Caucasian-vs-Asian |
2.965800E-01 |
| AfricanAmerican-vs-Asian |
1.254960E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.61030000000095E-05 |
| Normal-vs-Female |
7.77460318346357E-11 |
| Male-vs-Female |
1.955220E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.36369948456183E-10 |
| Normal-vs-Age(41-60Yrs) |
5.07540000027618E-08 |
| Normal-vs-Age(61-80Yrs) |
3.82780000000027E-05 |
| Normal-vs-Age(81-100Yrs) |
3.792000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.887000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.932400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.852000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.781200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.160000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.576000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.43836070726411E-12 |
| Classical-VS-Follicular |
2.16889999999914E-05 |
| Classical-VS-Other |
8.672200E-01 |
| Classical-VS-Normal |
1.29319999153665E-10 |
| Tall-VS-Follicular |
1.62903024403249E-12 |
| Tall-VS-Other |
1.597210E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
2.228400E-01 |
| Follicular-VS-Normal |
2.480400E-01 |
| Other-VS-Normal |
1.363160E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.6782000000013E-05 |
| Normal-vs-N1 |
1.14139808715663E-11 |
| N0-vs-N1 |
7.64830000000716E-05 |
|
|
